← board
CUE
Cue Biopharmadistress 6/10 · elevated risk$34.120%today-7% from 52w high
Oncology 2
Lead: solid tumors · target PD-1
Revenue
pre-revenue
Liquidity
$16M
Runway
0.7 yrs
Shares 1y
-95%
Price & events
+211.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.2%
1D
+22.8%
1W
+26.8%
1M
+105.3%
3M
+199.3%
6M
+27.8%
1Y
+53.1%
2Y
-89.2%
5Y
-90.8%
All
Overview
- Market Cap
- $138.03M
- Enterprise Value
- $121.65M
- Volume
- 12.05K
- 52 Week Range
- $5.31 – $36.78
- Total Shares
- 4.05M
- Float Shares
- 3.66M
- Short %
- 7.73%
- % Held by Insiders
- 17.18%
- % Held by Institutions
- 17.71%
- RVOL
- 0.10x
- Beta
- 2.46
Pipeline stages · 1 programs
CUE-101, KEYTRUDA®, PembrolizumabPD-1
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-01-04 | Phase 1 | CUE-101, KEYTRUDA®, Pembrolizumab | Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Carcinoma | 80 | completed |
| 2025-03-12 | Phase 1 | CUE-102 | Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Ovarian Cancer | 42 | completed |
Catalyst news & presentations · 5
- 2027Guided 40%regulatory submissionFiled (NDA/BLA)CUE-100 series · IND enabling studies on track for 2027 submissionSEC 8-K
- 2026-04-30partnershipAscendant-221 (UB-221) · Exclusive worldwide license for anti-IgE antibody, excluding China, Hong Kong, Macau, Taiwan.SEC 8-K
- 2026-04-01partnershipCUE-501 · Boehringer Ingelheim approved selection of first compound for lead optimization under collaboration, triggering $7.5M milestone payment.SEC 8-K
- 2025-11-06partnershipCUE-100 series · Cue Biopharma and ImmunoScape entered into a collaboration and license agreement to develop a novel T cell therapy for solid tumors using CUE-100 series and ImmunoScape's TCRs.SEC 8-K
- 2025-04-10partnershipCollaboration and License Agreement with Boehringer Ingelheim International GmbH for $12.0 million upfront payment.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-08-25LUCID CAPITAL MARKETSBuy
- 2025-04-02Citizens Capital MarketsMarket Outperform
- 2024-08-20StifelBuy
- 2024-07-26JMP SecuritiesMarket Outperform
- 2024-07-26Piper SandlerOverweight
Competitors — PD-1
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- NCNANuCana plc$28.3B · D2
- EXELEXELIXIS, INC.$13.8B · D0
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- CGEMCullinan Therapeutics, Inc.$1.1B · D1
- REPLReplimune Group, Inc.$906M · D2
- ALXOALX ONCOLOGY HOLDINGS INC$262M · D5
- BCABBioAtla, Inc.$107M · D8
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-22Cue Biopharma, Inc. announced that it has received $49.999926 million in funding from Cormorant Asset Management, LP, Threadneedle Asset Management Limited - marketscreener.com
- 2026-07-22Cue Biopharma (CUE) completes $49,999,927 Reg D Rule 506(b) raise - Stock Titan
- 2026-07-22ETFs Investing in Cue Biopharma, Inc. Stocks - TradingView
- 2026-07-21Bluestone Equity Partners Leads $55 Million Growth Investment in Poolhouse, the Technology-Enabled Cue Sports Business from the Founders of Topgolf and Puttshack - Premier Construction News
- 2026-07-21Cosmetologists take their cue - WAtoday
- 2026-07-21Cosmetologists take their cue - SMH.com.au
- 2026-07-21On cue with Kafui DEY: Prep trap: Why over-rehearsing for your next interview could be the worst thing you ever do - Business & Financial Times
- 2026-07-21Golden Dragon eyes ‘kilometre-scale’ gold anomalies at Cue - Mining.com.au
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.